SD230624-029 page 1 of 1

PharmLabs San Diego Certificate of Analysis

Sample GRDNT - 3.5 - BLDO



Delta9 THC ND THCa ND Total THC (THCa * 0.877 + THC) ND Delta8 THC ND

| Sample ID SD230624-029 (79805) | | Matrix Concentrate (Inhalable Cannabis Good) | |
|----------------------------------|-----------------------|--|--|
| Tested for 1 Week Distribution / | GRDNT | | |
| Sampled - | Received Jun 23, 2023 | Reported Jul 31, 2023 | |
| Analyses executed CANX | | | |

CANX - Cannabinoids Analysis Analyzed Jul 31, 2023 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoid analysis is approximately **#.806**% at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|--|-------------|-------------|-------------|----------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiorcin (CBDO) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiorcin (a-CBDO) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| 1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD) | 0.013 | 0.041 | ND | ND |
| 1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabivarin (Δ8-THCV) | 0.021 | 0.064 | ND | ND |
| Cannabidihexol (CBDH) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabutol (Δ9-THCB) | 0.013 | 0.038 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | ND | ND |
| Cannabidiphorol (CBDP) | 0.015 | 0.047 | ND | ND |
| exo-THC (exo-THC) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | ND | ND |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | 20.99 | 209.93 |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | 63.69 | 636.93 |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | ND | ND |
| Δ9-Tetrahydrocannabihexol (Δ9-THCH) | 0.024 | 0.071 | ND | ND |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabiphorol (Δ9-THCP) | 0.017 | 0.16 | ND | ND |
| Δ8-Tetrahydrocannabiphorol (Δ8-THCP) | 0.041 | 0.16 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-0-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | ND | ND |
| 9(R)-HHCP | 0.026 | 0.079 | 3.64 | 36.38 |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.005 | 0.16 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | ND | ND |
| Δ9-THC methyl ether (Δ9-MeO-THC) | 0.029 | 0.088 | ND | ND |
| Total THC (THCa \cdot 0.877 + Δ 9THC) | 0.027 | 0.000 | ND | ND |
| Total THC + Δ 8THC + Δ 10THC (THCa * 0.877 + Δ 9THC + Δ 8THC + Δ 10THC) | | | ND | ND |
| Total CBD (CBDa * 0.877 + CBD) | | | ND | ND |
| Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | 84.69 | 846.86 |
| Total Cannabinoids Analyzed | | | 88.32 | 883.24 |

UI Unidentified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected AUQ Detected >ULQL Above upper limit of linearity >ULQL Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count



DCC license: C8-0000098-LIC DEA license: RP0611043 ISO/IEC 17025:2017 Acc. L17-427-1



Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Mon, 31 Jul 2023 11:00:52 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1 This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to plagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an 'as received' back, indicated on therwise, when a das/real status is reported, that status is intended to be in accordance with redeard, state and local lows which are required for the customer to be in compliance. The measurement of uncertainty is own included in the Pass/real leaders, state and local lows which are required for the customer to be in compliance. The measurement of uncertainty is own included in the Pass/real leaders, state leaders, state and local lows which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/real leaders, state and local lows on the state real location uncertainty is not included in the Pass/real leaders, state locations on the state leaders and leaders.